Press Release

x2021-04-07MidCenturyWIDEV3.jpg.pagespeed.ic.B39J10Et_q.jpg.webp

Investor Relations

5/14/26

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Benzinga

4/8/26

Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives

GlobeNewswire

4/8/26

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

GlobeNewswire

4/6/26

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Benzinga

4/6/26

EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy

GlobeNewswire

4/2/26

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

GlobeNewswire

3/30/26

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

GlobeNewswire

3/18/26

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

GlobeNewswire

3/12/26

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

GlobeNewswire

3/11/26

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board